Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 20, 2015

Health Canada approves MolecuLight’s medical imaging device for wound care

Health Canada has granted approval for medical imaging firm MolecuLight's diagnostic medical imaging device, MolecuLight i:X, to treat chronic wounds.

Moleculight

Health Canada has granted approval for medical imaging firm MolecuLight’s diagnostic medical imaging device, MolecuLight i:X, to treat chronic wounds.

The handheld fluorescence imaging device provides real-time visualisation of bacteria in chronic wounds, and captures images like a point-and-shoot digital camera.

The device allows clinicians to effectively analyse the bacterial condition of chronic wounds with no patient contact or contrast agents.

MolecuLight founder Dr Ralph DaCosta said: "Canadian clinicians will now have a powerful new tool for more objective assessment of wound bacterial status and better antimicrobial treatment decision making."

"We will now be able to offer clinicians real-time diagnostic information about bacterial load at the bedside."

It also helps to quickly and easily visualise and precisely target clinically important bacteria in and around chronic wounds in real-time at the bedside, helping with targeted and precise treatment plans.

Bacteriological information provided by the device will help clinicians decide whether patients can be treated in a hospital, long-term treatment setting, at home, or in rural areas through telemedicine networks.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Clinical trials with MolecuLight i:X, including 180 patients, showed the device improved sample quality, healing rates, screen for high levels of bacteria and detect wound subsurface heavy bacterial load and subclinical local infection in patients.

MolecuLight CEO Craig Kennedy said: "This is a historic day for wound care. We will now be able to offer clinicians real-time diagnostic information about bacterial load at the bedside."

The company is involved in developing fluorescence image-guidance solutions to provide new information about bacterial wounds for better diagnostic and treatment decisions.


Image: MolecuLight i:X imaging device. Photo: courtesy of PRNewswire / MolecuLight.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU